Jefferies analyst Akash Tewari upgraded Regeneron Pharmaceuticals to Buy from Hold with a price target of $925, up from $675.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron May Win Big with New Drug
- Raymond James ups Regeneron to Market Perform as few downside catalysts remain
- Regeneron upgraded to Market Perform from Underperform at Raymond James
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial